

# CI GLOBAL VALUE FUND

## Q4-2020 Commentary



FUND	1 YEAR	3 YEAR	5 YEAR	10 YEAR	S.I.*
CI Global Value Fund, Series F	-0.77%	5.13%	6.14%	9.03%	4.49%
Benchmark: MSCI World Total Return Index	14.45%	11.77%	10.88%	13.26%	5.21%

\* Inception date of CI Global Value Fund Series F: August 8, 2000.  
Source: Altrinsic Global Advisors LLC a, as at December 31, 2020.

### PERFORMANCE SUMMARY

- Over the fourth quarter of 2020, CI Global Value Fund Series F (the Fund) returned 8.21% compared with the MSCI World Total Return Index (in Canadian-dollar terms), which returned 8.80%.
- The Fund underperformed its benchmark as a result of health care stocks generally lagging the strong performance of cyclical stocks over the period. This weighed on relative performance given the Fund's meaningful exposure to health care companies. Outside of health care, stock selection in the information technology and materials sectors detracted from performance. Stock selection in all other sectors contributed to performance, led by communication services, financials and consumer staples.
- The strong narrow leadership by highly-priced technology stocks that prevailed during most of 2020 gave way to a rebound in deep cyclical and lower-valuation businesses during the fourth quarter.

### CONTRIBUTORS TO PERFORMANCE

Chubb Ltd. was among the leading contributors to Fund performance. The company gained as a result of an improving vaccine outlook that reduces COVID-19 claims risks. In addition, Chubb reported strong earnings that highlighted margin expansion from an improving competitive environment. Baidu, Inc. was also among the leading contributors to performance. The company's share price rallied on an improving outlook for its autonomous car project. Baidu continues to report progress in its core search business with improving operating metrics.

### DETRACTORS FROM PERFORMANCE

Shares of Kinross Gold Corp. were adversely impacted by a rotation out of safe-haven assets this quarter. Biogen Inc. also detracted from performance. An independent advisory panel from the U.S. Food and Drug Administration (FDA) stated that Biogen's Alzheimer's drug has not shown efficacy. The FDA, which had previously been very positive about the drug, must now decide whether to approve the drug by March 2021.

### PORTFOLIO ACTIVITY

Healthcare Trust of America, Inc. was a new addition to the Fund. We believe the company offers attractive cash flow characteristics, including stable vacancy rates and resilient rents through economic cycles. We sold the Fund's position in Roche Holding AG as our investment thesis unfolded and the share price edged above our assessment of its intrinsic value.

## **MARKET OVERVIEW**

The “recovery trade” has been, and could continue to be, significant. The amount of fiscal and monetary stimulus has reached a level that is unprecedented in modern history. It is sensible to assume that the consequences, both good and bad, will be unprecedented as well. The temporary economic bridge that these policies have provided, and the rise in asset prices, is widely recognized and appreciated. Their negative consequences, however, are less widely known, discussed, or being contemplated in the media. This warrants prudence.

For more information, please visit [ci.com](https://www.ci.com).

---

## IMPORTANT DISCLAIMERS

Commissions, trailing commissions, management fees and expenses all may be associated with mutual fund investments. Please read the prospectus before investing. The indicated rates of return are the historical annual compounded total returns net of fees and expenses payable by the fund (except for figures of one year or less, which are simple total returns) including changes in security value and reinvestment of all dividends/distributions and do not take into account sales, redemption, distribution or optional charges or income taxes payable by any securityholder that would have reduced returns. Mutual funds are not guaranteed, their values change frequently and past performance may not be repeated.

This document is provided as a general source of information and should not be considered personal, legal, accounting, tax or investment advice, or an offer or a solicitation to buy or sell securities. Every effort has been made to ensure that the material contained in this document is accurate at the time of publication. Market conditions may change which may impact the information contained in this document. All charts and illustrations in this document are for illustrative purposes only. They are not intended to predict or project investment results. Individuals should seek the advice of professionals, as appropriate, regarding any particular investment. Investors should consult their professional advisors prior to implementing any changes to their investment strategies.

The comparison presented is intended to illustrate the Mutual Fund's historical performance as compared with the historical performance of widely quoted market indexes or a weighted blend of widely quoted market indexes. There are various important differences that may exist between the Mutual Fund and the stated indexes that may affect the performance of each. The objectives and strategies of the Mutual Fund result in holdings that do not necessarily reflect the constituents of and their weights within the comparable indexes. Indexes are unmanaged and their returns do not include any sales charges or fees. It is not possible to invest directly in market indexes.

Certain statements contained in this communication are based in whole or in part on information provided by third parties and CI Global Asset Management has taken reasonable steps to ensure their accuracy. Market conditions may change which may impact the information contained in this document.

Certain statements in this document are forward-looking. Forward-looking statements ("FLS") are statements that are predictive in nature, depend upon or refer to future events or conditions, or that include words such as "may," "will," "should," "could," "expect," "anticipate," "intend," "plan," "believe," or "estimate," or other similar expressions. Statements that look forward in time or include anything other than historical information are subject to risks and uncertainties, and actual results, actions or events could differ materially from those set forth in the FLS. FLS are not guarantees of future performance and are by their nature based on numerous assumptions. Although the FLS contained herein are based upon what CI Global Asset Management and the portfolio manager believe to be reasonable assumptions, neither CI Global Asset Management nor the portfolio manager can assure that actual results will be consistent with these FLS. The reader is cautioned to consider the FLS carefully and not to place undue reliance on FLS. Unless required by applicable law, it is not undertaken, and specifically disclaimed that there is any intention or obligation to update or revise FLS, whether as a result of new information, future events or otherwise.

Altrinsic Global Advisors, LLC. is the portfolio sub-advisor to certain funds offered and managed by CI Global Asset Management. CI Financial Corp. holds a minority interest in Altrinsic Global Advisors, LLC.

CI Global Asset Management is a registered business name of CI Investments Inc.

© CI Investments Inc. 2021. All rights reserved.

Published Date: **January xx**, 2021.